PA-NORDIC-PHARMA
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V. announced today that eminent oculoplastic surgeon John P. Fezza, MD will serve on its U.S. Medical Advisory Board (MAB) which includes Eric Donnenfeld, MD (New York), Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).
Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel. The FDA-cleared, cross-linked hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
“The entire U.S. Medical Advisory Board of Nordic Pharma is honored and delighted to welcome John Fezza, MD, a world class oculoplastic surgeon to our MAB,” said Eric Donnenfeld, MD, MAB Chair. “John will bring his unique perspective and understanding of the lacrimal drainage system to LACRIFILL’s novel treatment of dry eye disease.”
“I am thrilled to join this incredible Medical Advisory Board comprised of some of the most esteemed leaders in eyecare,” said John Fezza, MD. “They share a common vision of improving patient care, and understand the importance of treating dry eye disease. As the inventor of LACRIFILL Canalicular Gel, I believe we are launching a novel product that will change our approach to treating dry eyes.”
Nordic Pharma’s U.S. Medical Advisory Board brings together leading eye care providers from across the country, including ophthalmologists and optometrists in private practice and affiliated with major health systems. “John’s addition to our U.S. Medical Advisory Board provides historical and unique insights to this stellar group of optometry and ophthalmology leaders that will help set us up for a successful launch of LACRIFILL Canalicular Gel later this year,” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand.
Nordic Pharma is committed to engaging ophthalmologists and optometrists in the early launch stages of LACRIFILL Canalicular Gel. As part of the approach, members of the LACRIFILL team will be attending Vision Expo East, 2024 to share the benefits of LACRIFILL Canalicular Gel with optometrists and to discuss select pre-order opportunities.
“Optometry plays a crucial role in the management of dry eye disease as evident by prescribing the majority of medications to performing procedures like punctal occlusion,” said Paul M. Karpecki, O.D., FAAO. “The support for the profession shown by Nordic Pharma and the launch of the innovative product LACRIFILL Canalicular Gel, will go far in helping millions of patients suffering from dry eye disease.”
In addition to Dr. Fezza’s appointment, the LACRIFILL launch is further benefitting from Todd Love being hired as National Sales Director by Inizio Engage. “Todd comes to us with a strong legacy of leadership and camaraderie in the eye care industry for nearly 25 years,” said Jai G. Parekh, MD, MBA, Chief Commercial Officer of Nordic Pharma Eye Care U.S. “He is a ‘true natural’ and after years of experience at Alcon, Bausch & Lomb, and more recently, Sight Sciences, we look to him to help lead our initiatives in the field with our esteemed sales force. His acumen will be critical to our launch of LACRIFILL Canalicular Gel within the eye care community; I look forward to working closely with him.”
About John P. Fezza, M.D.
Dr. Fezza has been a member of the Center For Sight team since 1998 and specializes in cosmetic facial and laser surgery. He earned his bachelor’s degree from Duke University and received his medical education at New York Medical College, where he was President of the Alpha Omega Alpha honors society. He completed his internship in general surgery and residency in ophthalmology at Yale University and his two-year fellowship in oculofacial plastic surgery at Vanderbilt University. In addition, he completed a second fellowship in cosmetic surgery sponsored by the American Academy of Cosmetic Surgery. He has many years of subspecialty training focusing solely on eyelid, face and neck surgery, which he considers his passion.
Dr. Fezza has held many prestigious national positions in medical societies, including the position of Past President of the American Board of Facial Cosmetic Surgery, and Past Treasurer of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS). In 2016, he was honored with the ASOPRS Research Award and in 2019 he received the Henry Baylis Cosmetic Surgery Award for longstanding contributions in the field of cosmetic facial surgery.
A nationally recognized author and lecturer on cosmetic facial and laser surgery, Dr. Fezza is a member of the American Academy of Cosmetic Surgery, the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) and the American Board of Ophthalmology. Dr. Fezza is a well-respected pharmaceutical consultant, lecturer, and master trainer. He serves on advisory boards for Allergan, Revance Therapeutics and is involved as an investigator in FDA clinical trials. In addition, he is an ad hoc preceptor for ASOPRS fellows and was an Associate Clinical Professor in Oculoplastics at the University of South Florida. Dr. Fezza holds multiple patents for treatment of dry eye disease and medical devices for facial fillers.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.
Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314786115/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Catch the Best Prime Day Offers on Smart Home Must-Haves: EZVIZ Rolls Out Jaw-Dropping Deals on Tried-and-True Cameras and Entryway Innovations for Everyday Peace of Mind8.7.2025 11:30:00 CEST | Press release
This Prime Day, EZVIZ, an internationally trusted name in smart home security, introduces a handpicked selection of exclusive offers that protect homes from the very first point of contact. For households that value safety around the home and especially at the very threshold, this is a moment to invest in home security that is as advanced as it is effortless. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702338311/en/ From 8 to 11 July, homeowners can seize the window on EZVIZ Prime Day deals on Amazon UK, featuring EZVIZ’s best-loved smart cameras, expertly bundled packages, and a complete range of entry products. These limited-time savings offer a rare opportunity to elevate home protection, no matter for a bustling city apartment or a sprawling family residence. Here are some top-rated deals: CP3 Pro Video Doorbell with solar panel – now £49.98, was £79.99 An intelligent welcome with built-in protection. Powered by an
CapVest and Parquest Agree Terms on IPN’s Acquisition of Sopral8.7.2025 10:00:00 CEST | Press release
Inspired Pet Nutrition (“IPN”), the fast-growing pet food company controlled by CapVest Partners LLP (“CapVest”), and Parquest, a leading investment firm, have agreed terms on the acquisition of Sopral, a prominent branded pet food platform serving the European market, with manufacturing operations based in France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708134461/en/ Sopral products The transaction is subject to customary regulatory approvals and closing conditions. Financial terms have not been disclosed. Based in Pléchâtel, Brittany, France, Sopral is a leading manufacturer of branded premium dry petfood with a comprehensive range of high-quality nutritional solutions, including Pro-Nutrition Prestige, Pure Life and Protect brands. Sopral has a strong footprint and reputation in France and a fast growing online and international market presence in over 50 countries around the world. Employing over 130 people, th
Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release
At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release
Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime
Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release
Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom